AGTC to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Applied Genetic Technologies Corporation (Nasdaq: AGTC) announced participation in the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Applied Genetic Technologies Corporation (Nasdaq: AGTC) announced participation in the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021. The company is focused on developing gene therapies for rare diseases and is currently conducting human clinical trials using AAV-based technologies.
AGTC's advanced programs aim to treat conditions like X-linked retinitis pigmentosa and achromatopsia. Interested parties can access audio webcasts of the presentation via the company's website.
Details
News Market Reaction – AGTC
The recorded move for AGTC in the trading session of this news was +0.29%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that management will be participating in a company presentation at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13th, 2021.
Audio webcasts of the presentation can be accessed by visiting http://ir.agtc.com/eventsand-presentations. A replay will be available on the Company's website following the events.
About AGTC
AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. AGTC’s most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM B3 and ACHM A3). Its preclinical programs build on the Company’s industry leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders. In recent years AGTC has entered into strategic partnerships with companies including Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, and Bionic Sight, LLC, an innovator in the emerging field of optogenetics and retinal coding.
IR CONTACT:
Jonathan Nugent
Stern IR
T: 212-698-8698
Jonathan.nugent@sternir.com
Corporate Contacts:
Stephen Potter
Chief Business Officer
Applied Genetic Technologies Corporation
T: (617) 413-2754
spotter@agtc.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.